troglitazone has been researched along with Liver Steatosis in 19 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventy-eight patients with type 2 diabetes adequately controlled with glibenclamide were randomly allocated to a troglitazone (400 mg/d)-added group (n = 40) or a control group without placebo (n = 38) and monitored for 24 weeks." | 6.70 | Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. ( Hata, S; Ikemoto, S; Inoue, Y; Katoh, S; Matsushima, M; Tajima, N; Yokoyama, J, 2001) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 5.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| "Seventy-eight patients with type 2 diabetes adequately controlled with glibenclamide were randomly allocated to a troglitazone (400 mg/d)-added group (n = 40) or a control group without placebo (n = 38) and monitored for 24 weeks." | 2.70 | Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. ( Hata, S; Ikemoto, S; Inoue, Y; Katoh, S; Matsushima, M; Tajima, N; Yokoyama, J, 2001) |
| "Nonalcoholic steatohepatitis (NASH) is caused by an elevation in oxidative stress, which might further lead to hepatic fibrogenesis." | 1.38 | Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways. ( Hwang, SL; Shih, PH; Yeh, CT; Yen, GC, 2012) |
| "In contrast, active steatohepatitis, progression of fibrosis, and requirement of antidiabetic medications were seen in patients unable to achieve lifestyle modifications." | 1.35 | Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? ( Al-Osaimi, AM; Argo, CK; Caldwell, SH; Iezzoni, JC, 2009) |
| "Troglitazone is a newly developed antidiabetic drug and is indicated to be useful for the treatment of patients with type II diabetes mellitus." | 1.31 | Troglitazone prevents fatty changes of the liver in obese diabetic rats. ( Abe, S; Akiyama, T; Jia, DM; Otsuki, M; Tabaru, A, 2000) |
| "Troglitazone is a thiazolidinedione and peroxisome proliferator-activated receptor gamma (PPARgamma) ligand used to treat diabetes mellitus type II." | 1.31 | A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. ( Battle, EH; Caldwell, SH; Hespenheide, EE; Iezzoni, JC; Redick, JA; Sheppard, BL, 2001) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 1.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 14 (73.68) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martins, FO | 1 |
| Delgado, TC | 1 |
| Viegas, J | 1 |
| Gaspar, JM | 1 |
| Scott, DK | 1 |
| O'Doherty, RM | 1 |
| Macedo, MP | 1 |
| Jones, JG | 1 |
| Argo, CK | 1 |
| Iezzoni, JC | 2 |
| Al-Osaimi, AM | 1 |
| Caldwell, SH | 2 |
| Cusi, K | 1 |
| Kakiuchi-Kiyota, S | 1 |
| Arnold, LL | 1 |
| Yokohira, M | 1 |
| Koza-Taylor, P | 1 |
| Suzuki, S | 1 |
| Varney, M | 1 |
| Pennington, KL | 1 |
| Cohen, SM | 1 |
| Shih, PH | 1 |
| Hwang, SL | 1 |
| Yeh, CT | 1 |
| Yen, GC | 1 |
| Wagnerberger, S | 1 |
| Spruss, A | 1 |
| Kanuri, G | 1 |
| Stahl, C | 1 |
| Schröder, M | 1 |
| Vetter, W | 1 |
| Bischoff, SC | 1 |
| Bergheim, I | 1 |
| Angulo, P | 2 |
| Schadinger, SE | 1 |
| Bucher, NL | 1 |
| Schreiber, BM | 1 |
| Farmer, SR | 1 |
| Moreno Sánchez, D | 1 |
| Khashab, M | 1 |
| Chalasani, N | 1 |
| Krentz, AJ | 1 |
| Jia, DM | 1 |
| Tabaru, A | 1 |
| Akiyama, T | 1 |
| Abe, S | 1 |
| Otsuki, M | 1 |
| Sanyal, AJ | 1 |
| Hespenheide, EE | 1 |
| Redick, JA | 1 |
| Battle, EH | 1 |
| Sheppard, BL | 1 |
| Katoh, S | 1 |
| Hata, S | 1 |
| Matsushima, M | 1 |
| Ikemoto, S | 1 |
| Inoue, Y | 1 |
| Yokoyama, J | 1 |
| Tajima, N | 1 |
| Maher, J | 1 |
| Harano, Y | 1 |
| Lindor, KD | 1 |
| Bedoucha, M | 1 |
| Atzpodien, E | 1 |
| Boelsterli, UA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)[NCT00227110] | Phase 4 | 55 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for troglitazone and Liver Steatosis
| Article | Year |
|---|---|
Current best treatment for non-alcoholic fatty liver disease.
Topics: Antioxidants; Chromans; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Fatty L | 2003 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2007 |
[Lipodystrophia].
Topics: Animals; Cardiomyopathy, Hypertrophic; Chromans; Diabetes Mellitus; Diagnosis, Differential; Fatty L | 2001 |
1 trial available for troglitazone and Liver Steatosis
| Article | Year |
|---|---|
Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Topics: Adipose Tissue; Aged; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2001 |
14 other studies available for troglitazone and Liver Steatosis
| Article | Year |
|---|---|
Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia.
Topics: Animals; Chromans; Fatty Liver; Hyperinsulinism; Hypoglycemic Agents; Male; Protective Agents; Rats; | 2016 |
Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?
Topics: Biopsy; Chromans; Clinical Trials as Topic; Drug Administration Schedule; Exercise; Fatty Liver; Hum | 2009 |
Thiazolidinediones in NASH. An odd couple meant to be?
Topics: Chromans; Fatty Liver; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Thiazolid | 2009 |
Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Body Weight; Cell Growth Processes; Cell Hypoxia; Ce | 2011 |
Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways.
Topics: Animals; Anthocyanins; Cell Line, Tumor; Chromans; Drug Synergism; Extracellular Signal-Regulated MA | 2012 |
Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model.
Topics: Alanine Transaminase; Animals; Butyrates; Cell Line; Cell Proliferation; Chromans; Disease Models, A | 2013 |
PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.
Topics: Acetyl-CoA Carboxylase; Animals; Azo Compounds; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; C | 2005 |
Non-alcoholic steatohepatitis.
Topics: Chromans; Contraindications; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic | 1999 |
Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Topics: Age Factors; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; | 2000 |
Insulin resistance and nonalcoholic steatohepatitis: fat or fiction?
Topics: Chromans; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Thiazoles; Thiazo | 2001 |
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Chromans; Fatty Liver; Female; Humans; Hypoglycemic Agents; Obesity; Pi | 2001 |
Antidiabetic treatment for NASH?
Topics: Animals; CCAAT-Enhancer-Binding Proteins; Chromans; Diabetes Mellitus; DNA-Binding Proteins; Fatty L | 2001 |
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Topics: Adult; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fat | 2001 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male | 2001 |